For US Healthcare Professionals
XARELTO® vascular dose*
An approved treatment strategy for symptomatic PAD patients who have recently undergone LER†‡1,2
PRESCRIBE THE XARELTO® VASCULAR DOSE*: The FIRST and ONLY treatment approach indicated to help reduce risk of major thrombotic vascular events† in patients with PAD, including patients after a recent LER procedure due to symptomatic PAD1,2
Tablets not shown to actual size.
• When starting therapy after a successful LER procedure, initiate once hemostasis has been established. No dose adjustment based on CrCl.1
The FIRST and ONLY DOAC indicated to help reduce major cardiovascular events§ in patients with CAD and major thrombotic vascular eventsII in patients with PAD1,5-8
ALI = acute limb ischemia; BID = twice daily; CV = cardiovascular; DOAC = direct oral anticoagulant; ISTH = International Society on Thrombosis and Haemostasis; LER = lower extremity revascularization; MI = myocardial infarction; PAD = peripheral artery disease; QD = once daily; TIMI = Thrombolysis in Myocardial Infarction.
*XARELTO® 2.5 mg twice daily plus aspirin (100 mg in clinical trial; 75 mg to 100 mg in practice) once daily.
†Reduction of a composite of myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology.
‡Treatment schedule: XARELTO® 2.5 mg twice daily versus placebo; all patients received aspirin 100 mg once daily as background therapy.
§Major cardiovascular events were a composite of cardiovascular death, myocardial infarction, and stroke.
IIMajor thrombotic vascular event is the composite of myocardial infarction, ischemic stroke, cardiovascular death, acute limb ischemia, and major amputation of a vascular etiology in patients with PAD, including patients who have recently undergone an LER procedure due to symptomatic PAD.
¶Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. These events occurred during treatment or within 2 days of stopping treatment in the safety analysis set.
#1.6%/year (n=263) for patients taking XARELTO® 2.5 mg BID + aspirin 100 mg QD (N=9134) and 0.9%/year (n=144) for patients taking placebo + aspirin 100 mg QD (N=9107).
